论文部分内容阅读
目的观察低剂量替吉奥一线治疗高龄晚期胃癌的疗效及安全性.方法治疗组36例高龄晚期胃癌患者给予低剂量替吉奥口服化疗,对照组32例给予最佳支持治疗,3个周期后评价疗效,并观察不良反应.结果治疗组和对照组的客观有效率分别为22.2%和3.1%,疾病控制率分别为58.3%和32.3%,两组差异均有显著性(P﹤0.05).治疗组不良反应主要为血液学毒性、消化道反应和疲乏等,但较轻微.结论低剂量替吉奥口服治疗高龄晚期胃癌疗效较好,不良反应较轻,患者耐受性较好.“,”Objective: To observe the efficacy and safety of low-dose S-1 in the first-line treatment of elderly patients with advanced gastric cancer. Methods: The therapy group included 36 elderly patients was treated with low-dose S-1 oraly. The control group included 32 cases was treated with best supportive care. The efficacy and adverse reaction were evaluated after 3 cycles of chemotherapy. Results: The objective response rates (RR) of the therapy group and the control group were 22.2% and 3.1%. The disease control rates (DCR) were 58.3% and 32.3%. There were significant differences between two groups (P﹤0.05). The adverse reactions in the therapy group were mild, including hematological toxicity, digestive tract reaction and fatigue. Conclusion: Low-dose S-1 oraly had good efficacy, mild adverse reactions and favorable tolerability in the treatment of elderly patients with advanced gastric cancer.